"GLP-1 receptor agonists, CKD, and eGFR trajectory – Authors' reply" by Katherine R Tuttle

Selected Works of Katherine R. Tuttle, MD, FASN, FACP, FNKF

Follow Contact

Article

GLP-1 receptor agonists, CKD, and eGFR trajectory – Authors' reply

The Lancet Diabetes & Endocrinology (2018)

Katherine R Tuttle, University of Washington
Mark C Lakshmanan, Eli Lilly and Company
Brian Rayner, University of Cape Town
Robert S Busch, Albany Medical College
Alan G Zimmermann, Eli Lilly and Company
D Bradley Woodward, Eli Lilly and Company
Fady T Botros, Eli Lilly and Company

Link

Disciplines

Medicine and Health Sciences,
Endocrinology, Diabetes, and Metabolism,
Internal Medicine and
Endocrinology

Publication Date

October 1, 2018

DOI

10.1016/s2213-8587(18)30239-0

Citation Information

Katherine R Tuttle, Mark C Lakshmanan, Brian Rayner, Robert S Busch, et al.. "GLP-1 receptor agonists, CKD, and eGFR trajectory – Authors' reply" The Lancet Diabetes & Endocrinology Vol. 6 Iss. 10 (2018) p. 765
Available at: http://works.bepress.com/katherine-tuttle/174/